MNG74
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.317
- MYOGENESIS+0.313
- COAGULATION+0.259
- TNFA_SIGNALING_VIA_NFKB+0.247
- KRAS_SIGNALING_DN+0.224
- APICAL_JUNCTION+0.190
- HYPOXIA+0.186
- UV_RESPONSE_UP+0.173
- P53_PATHWAY+0.157
- CHOLESTEROL_HOMEOSTASIS+0.154
Top 10 suppressed
- PROTEIN_SECRETION-0.510
- E2F_TARGETS-0.458
- G2M_CHECKPOINT-0.414
- MYC_TARGETS_V1-0.407
- ANDROGEN_RESPONSE-0.368
- INTERFERON_ALPHA_RESPONSE-0.290
- MTORC1_SIGNALING-0.228
- MITOTIC_SPINDLE-0.225
- ALLOGRAFT_REJECTION-0.224
- PEROXISOME-0.199
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A401-01A-11R-A239-07 | — | B | 0.829 |
| 2 | SJEPD001517_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.824 |
| 3 | SRR4195649 | — | — | 0.797 |
| 4 | R7 | — | — | 0.792 |
| 5 | TCGA-A7-A425-01A-11R-A24H-07 | — | A | 0.785 |
| 6 | TCGA-B6-A40B-01A-11R-A239-07 | — | B | 0.784 |
| 7 | R236 | — | — | 0.783 |
| 8 | R37 | — | — | 0.781 |
| 9 | AUR-AER7-TTM4-A-1-1-R-A742-41 | — | E | 0.779 |
| 10 | SJEPD001525_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.317 | Inavolisib | — uncovered |
| MYOGENESIS | 0.313 | Inavolisib | — uncovered |
| COAGULATION | 0.259 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.247 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.224 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.186 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.173 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.157 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.154 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.141 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.114 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.114 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.102 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.099 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.091 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.071 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.059 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.039 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.010 | Inavolisib | — uncovered |